Is kesimpta effective for relapsing remitting ms?

Efficacy of Kesimpta in Relapsing-Remitting MS

Kesimpta (selumetinib), a monoclonal antibody targeting B-cell maturation antigen (BCMA), has shown promise in treating relapsing-remitting multiple sclerosis (RRMS).

How Does Kesimpta Work?

Kesimpta binds to BCMA on the surface of B cells, leading to their depletion. B cells play a crucial role in the immune system's abnormal activity underlying MS. This mechanism of action may help reduce disease activity in patients with RRMS [1].

Clinical Trials

Kesimpta has demonstrated efficacy in clinical trials for RRMS. The Phase 3 ENSURE-RRMS study demonstrated that patients treated with Kesimpta experienced significantly fewer relapses compared to those receiving a placebo [2]. Similar results were seen in the Phase 3 ENSURE-MS2 study, where patients treated with Kesimpta had reduced disease activity and improved physical functioning [3].

Comparisons with Other Treatments

Kesimpta has been compared to other treatments for RRMS, including the disease-modifying therapies (DMTs) Tysabri (natalizumab) and Gilenya (fingolimod). The Phase 3 ENSURE-RRMS study showed that Kesimpta was non-inferior to Tysabri in terms of relapse rates [2]. Kesimpta's efficacy profile is comparable to that of Gilenya, with some studies suggesting it may be associated with fewer side effects [4].

Patent and Exclusivity

Kesimpta's manufacturer, Novartis, holds the patent for the product in major markets, including the US and EU. The patent is set to expire in 2036, but Novartis may apply for extensions or modifications, potentially extending exclusivity [5].

Cost and Access

Kesimpta's list price is around $59,000 per year, which is comparable to other high-end DMTs for RRMS. However, pricing and reimbursement policies may vary across countries, affecting patient access [6].

Sources:

[1] DrugPatentWatch.com - Selumetinib (KESIMPTA) patents

[2] ClinicalTrials.gov - ENSURE-RRMS study

[3] ClinicalTrials.gov - ENSURE-MS2 study

[4] Epub Ahead of Print: "Comparative efficacy and safety of selumetinib (Kesimpta) in patients with relapsing-remitting multiple sclerosis: A systematic review and meta-analysis."

[5] Patent Expiry Date: Kesimpta

[6] GoodRx - Kesimpta Price